Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma

por Salama, April K.S.
Publicado 2013

First-line treatment of metastatic melanoma: role of nivolumab

por Force, Jeremy, Salama, April KS
Publicado 2017

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

por Gangadhar, Tara C, Salama, April KS
Publicado 2015

Updates in Therapy for Advanced Melanoma

por Singh, Bhavana P., Salama, April K. S.
Publicado 2016

A Review of Immune-Mediated Adverse Events in Melanoma

por Kennedy, Lucy Boyce, Salama, April K. S.
Publicado 2019

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

por Tan, Irena, Malinzak, Michael, Salama, April K. S.
Publicado 2018

Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease

por Dietz, Hilary, Weinmann, Sophia C, Salama, April K
Publicado 2021

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

por Bostwick, A Doran, Salama, April K, Hanks, Brent A
Publicado 2015

Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations

por Grant, Michael J, DeVito, Nicholas, Salama, April K S
Publicado 2018

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec

por Lebhar, Jamie, Jacobs, Jennifer, Faraz, Khushnood, Salama, April K.S., Mosca, Paul J.
Publicado 2023

Overall Survival Improved for Contemporary Patients with Melanoma: A 2004–2015 National Cancer Database Analysis

por Farrow, Norma E., Turner, Megan C., Salama, April K. S., Beasley, Georgia M.
Publicado 2020

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

por Sarver, Melissa, Brown, Michael C., Rhodin, Kristen E., Salama, April K. S., Beasley, Georgia M.
Publicado 2021

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

por Lowe, Jared R., Perry, Daniel J., Salama, April K. S., Mathews, Clayton E., Moss, Larry G., Hanks, Brent A.
Publicado 2016

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

por Gajewski, Thomas F, Salama, April KS, Niedzwiecki, Donna, Johnson, Jeffrey, Linette, Gerald, Bucher, Cynthia, Blaskovich, Michelle A, Sebti, Said M, Haluska, Frank
Publicado 2012

Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy

por Salama, April K. S., de Rosa, Nicole, Scheri, Randall P., Pruitt, Scott K., Herndon, James E., Marcello, Jennifer, Tyler, Douglas S., Abernethy, Amy P.
Publicado 2013

TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF...

por Kirkpatrick, John, Franklin, Heather, Torok, Jordan, Floyd, Scott, Anders, Carey, Fecci, Peter, Salama, April, Clarke, Jeffrey, George, Daniel, Crapo, James, Peters, Katherine
Publicado 2019

SAT-414 A Single Center Retrospective Analysis and Review of Endocrinopathies from Immune Checkpoint Inhibitors Between 2007 and 2017

por Shariff, Afreen Idris, Qamar, Ali, Rivera, Jonathan Velez, Mozingo, Lauren Kaye, Thacker, Connie, Rushing, Christel, Jung, Sinho, Salama, April Kelly, D’Alessio, David A
Publicado 2020

Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer

por Dikshit, Anushka, Lu, Junqi, Ford, Amy E., Degan, Simone, Jin, Yingai J., Sun, Huiying, Nichols, Amanda, Salama, April K.S., Beasley, Georgia, Gooden, David, Zhang, Jennifer Y.
Publicado 2021

Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events

por Oswalt, Cameron J., Al-Rohil, Rami N., Theivanthiran, Bala, Haykal, Tarek, Salama, April K.S., DeVito, Nicholas C., Holtzhausen, Alisha, Ko, Dennis C., Hanks, Brent A.
Publicado 2022

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics

por Rossfeld, Kara, Hade, Erinn M., Gangi, Alexandra, Perez, Matthew, Kinsey, Emily N., Grabska, Joanna, Ederle, Ashley, Zager, Jonathan, Salama, April K., Olencki, Thomas E, Beasley, Georgia M
Publicado 2017